Nico van Zandwijk Head of the Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands Former secretary and chairman of.

Slides:

Advertisements

Similar presentations

Advertisements

Treatment in Advanced Non-Small Cell Lung Cancer.

Preventing Cancer with Healthy Life Styles Li-Fen L. Chang, M.D., Ph.D. Radiation Oncology SOMC Cancer Center.

An Introduction to Cancer Biology Geoff Mitchell April 24, 2007.

Risk factors of non-smoking lung cancer Po-Yin Chang.

April 6, o What is cancer? o Cancer statistics o Cancer prevention and early detection o Cancer disparities o Cancer survivorship o Cancer research.

Tuesday, June 23, Today’s discussion General cancer statistics Cancer in Canada PEI Statistics at a glance Impact.

First HAYAT Annual Patients Forum – 21 st March 2010 – SAS, Kuwait First HAYAT Annual Patients Forum 21 st March 2010 Al Hashimi II Ballroom – SAS Hotel.

Cancer Card Game Answers etc.

CRC-1 The Need for 3rd-Line Therapy in Non-Small Cell Lung Cancer Frances A. Shepherd, MD Scott Taylor Chair in Lung Cancer Research Princess Margaret.

ANZDATA Registry Annual Report 2013 CANCER CHAPTER 10.

Palliative Chemotherapy Dr. Oscar S. Breathnach Consultant Medical Oncologist Palliative Care Multidisciplinary Study Day Beaumont Hospital Sept. 19 th,

* For those free of cancer at beginning of age interval. Source: DevCan: Probability of Developing or Dying of Cancer Software, Version Statistical.

Epidemiology of Oral Cancer Module 1:. Epidemiology of Cancer, U.S.

* For those free of cancer at beginning of age interval. Source: DevCan: Probability of Developing or Dying of Cancer Software, Version Statistical.

A randomized trial of prophylactic cranial irradiation (PCI) versus no PCI in extensive disease small cell lung cancer after a.

New Developments in Cancer Treatment Dulcinea Quintana, MD.

Cancer Among Native Americans in Arizona and New Mexico Data Provided by Arizona Cancer Registry at the Arizona Department of Health Services and the New.

Cell Cycle Regulation and Cancer. 3 Checkpoints Control the cell cycle (inspection points) Make sure the cell is ready to move into the next phase. Mitosis.

Brittany Houghton Biochemistry What is cancer?  A group of diseases characterized by uncontrolled growth and spread of abnormal cells.  Considered.

Regulating the Cell Cycle Biology 392 Chapter 10-3.

Breast Cancer: Treatment or Not? HFE 742 Cathy Simmons November 10, 2005.

WE WILL ALL DIE OF CANCER If something else doesn’t kill us first HYPOTHESIS:

Eric Van Cutsem Head, Digestive Oncology, University Hospital Gasthuisberg and Professor of Internal Medicine, University of Leuven, Belgium Published.

HEAD/NECK OF THE SKIN ANALYTIC vs. NON-ANALYTIC by YEAR N = 1800.

Slides last updated: October Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM. GLOBOCAN 2008 v2.0, Cancer Incidence and Mortality.

RCS 6080 Medical and Psychosocial Aspects of Rehabilitation Counseling Cancer.

Role of the Surgeon in Cancer Management A. Responsible for the initial diagnosis and management of solid tumors. B. Responsible for the Definitive Surgical.

CANCER CONTROL NHPA’s. What is it? Cancer is a term to describe a diverse group of diseases in which some of the cells in body become defective. The following.

Introduction Ignace Vergote, MD Department of Obstetrics and Gynaecology Gynaecologic Oncology Catholic University of Leuven Leuven, Belgium.

Treatment Regimens of HER2+ Adjuvant Patients (Actuals) Source: Genentech ASCO 2005 (data release) Nov 2006 (Approval)

Tools to Access the Latest Cancer Statistics Paul Miller Washington Reporting Fellowships program presentation April 15, 2013.

Dr Heather O Dickinson Department of Child Health University of Newcastle

A paradigm shift in the treatment of advanced lung cancer: survival and symptom benefits with Tarceva Tudor-Eliade Ciuleanu Cancer Institute Ion Chiricuta.

Homework #3 is due 11/19 Bonus #2 is posted. Cancer: is the loss of control over cell division. Tumors are normal cells that are dividing inappropriately.

Challenges for the treatment of pancreatic and renal cell cancer Nick Thatcher Christie Hospital NHS Trust Manchester, UK.

Cancer “whiteboard” presentation ●Name of cancer (what type), where can it occur? ●Function of body part that it affects ●Causes (genetic, environmental…)?

Bertrand Coiffier Professor, Department of Haematology, Hospices Civils de Lyon and University Claude Bernard, Lyon, France Prior posts at the Edouard-Herriot.

CD-1 Second-line Chemotherapy for Hormone Refractory Prostate Cancer Disease Background Nicholas J. Vogelzang, MD Director Nevada Cancer Institute CD-1.

Slides last updated: March Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray, F. GLOBOCAN.

FRENCH high-resolution studies - Breast cancer: 1990, 1997, 2003, 2010 ? - Colorectal cancer: 1990, 1995, 2000, 2005, 2010 ? - Prostate cancer: 1995,

Cancer: causes abnormal and uncontrolled cell growth to occur within body Because cancer cells continue to grow and divide, they are different from normal.

What the cancer tools show for London Vivian Mak National Cancer Intelligence Network London Public Health Knowledge and Intelligence Network meeting Wednesday.

Cancer Facts MS JYOTI SHAH CONSULTANT UROLOGICAL SURGEON SOURCE: CANCER RESEARCH UK.

Omega Best Cancer Hospital - India

The Changing Face of Cancer in Iowa

Challenges for the treatment of breast cancer

2 Incidence SABER This module presents statistics from Chapter 2: Incidence Ontario Cancer Statistics 2016 Chapter 2: Incidence.

Su K. Metcalfe, MD, MPH, Michael T

US Mortality, 2003 No. of deaths % of all deaths Rank Cause of Death

5 Prevalence ZEINAB This module presents statistics from Chapter 5: Prevalence Ontario Cancer Statistics 2016 Chapter 5: Prevalence.

Incidence of nonskin cancers at five years

The Nurse View: Best Practices in Advanced Non-Small Cell Lung Cancer

Volume 384, Issue 9945, Pages (August 2014)

5 Prevalence Ontario Cancer Statistics 2016 Chapter 5: Prevalence.

Kaplan–Meier curves for a, b) progression-free survival (PFS) and c, d) overall survival (OS) in a, c) large-cell neuroendocrine carcinoma patients and.

The Changing Face of Cancer in Iowa

Oncology Market Forecast

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

The 20 Most Common Cancers in 2012

The Influence of the Evolution of First-Line Chemotherapy on Steadily Improving Survival in Advanced Non-Small-Cell Lung Cancer Clinical Trials Krista.

Meta-Analysis of First-Line Therapies in Advanced Non–Small-Cell Lung Cancer Harboring EGFR-Activating Mutations Benjamin Haaland, PhD, Pui San Tan,

Targeting the Androgen Pathway: Current Best Practice and Future Directions.

Aim: What do you want to know about cancer? (addressing your concerns)

Maintenance Therapy and Advanced Non–Small-Cell Lung Cancer: A Skeptic's View Martin J. Edelman, MD, Thierry Le Chevalier, MD, Jean-Charles Soria, MD,

Siwei Zhang Rongshou Zheng

Using Q-learning Method in Identify Optimal Treatment Regime

APLCC POSTER SESSION 2 - WEDNESDAY, NOVEMBER 28

Kaplan–Meier analysis of PFS and OS in patients with advanced non-small cell lung cancer with adenocarcinoma histology with time since start of first-line.

Trends of mortality rates in the USA between 1930 and 2000 in males according to cancer site. –––––: stomach; ·······: prostate; –– –– ––: colon and rectum;

Presentation transcript:

Nico van Zandwijk Head of the Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands Former secretary and chairman of the European Organisation for Research and Treatment of Cancer (EORTC) Lung Cancer Group Member of the Board of Directors of the International Association for the Study of Lung Cancer (IASLC) Member of the Advisory Board of the Thoracic Section of the French National Cancer Institute (INCa) Is the co-author of more than 180 peer- reviewed international papers and chapters Will take up the post of inaugural director of a new thoracic oncology institute at the University of Sydney, Australia, in March 2008 Netherlands Cancer Institute

Challenges for the first- and second-line treatment of non-small cell lung cancer Nico van Zandwijk Netherlands Cancer Institute Amsterdam, The Netherlands

Thursday 7 February 2008 Agenda 14.10Chair’s opening Nico van Zandwijk 14.15The new kid on the block: bevacizumab in first-line NSCLC Nick Thatcher 14.45First choice in second line: erlotinib in NSCLC Romàn Pérez-Soler 15.15Discussion 15.30Coffee break 16.00Meet the Expert sessions

Lung cancer is the most common form of cancer in the world Lung Breast Bowel Stomach Liver Prostate Cervix Oesophagus Bladder Leukaemia Oral cavity Pancreas Kidney Ovary Uterus Brain and CNS Melanoma Larynx Thyroid Non-Hodgkin’s lymphoma Ferlay J, et al. Globocan 2002: Cancer incidence, mortality and prevalence worldwide

American Cancer Society: cancer facts and figures 2007 Incidence Mortality Lung cancer has high incidence and mortality Estimated new cases/ deaths in the USA (per year) 250, , , ,000 50,000 0 Breast ColonPancreasKidneyLung

Advanced NSCLC: what are the treatment goals for patients? ‘Longer life’ –improved overall survival ‘Better life’ –agents for patients who are not suitable for chemotherapy –improvement of disease-related symptoms –better-tolerated regimens; reduced toxicity –prolonged time to disease progression –improved disease control rate –improved quality of life NSCLC = non-small cell lung cancer

NSCLC: what are the challenges that we face in the next decade? Determine how new agents can be best used in conjunction with current treatment modalities Determine how best to tailor therapy for the patient Expanding therapeutic options without increased toxicity for elderly and performance status 2 patients Expanding the eligible patient population for novel targeted agents Treatment options beyond second line